Text Size

Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Novartis
Information provided by:
Tehran University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01016093
First received: November 17, 2009
Last updated: July 25, 2011
Last verified: July 2011
History of Changes
  Purpose

This is prospective randomized, double blind study designed to evaluate the use of zoledronic acid in the prevention prevention of bone loss post allogenic BMT done for beta-thalassemia major patients.


Condition Intervention Phase
Beta-Thalassemia
Bone Marrow Transplantation
 Drug: Zoledronic acid
Drug: Placebo
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients: A Prospective Pilot Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Tehran University of Medical Sciences:

Primary Outcome Measures:
  • To describe the percent change in the lumbar spine (L1 to L4) BMD, as measured by dual energy X-ray absorptiometry, at 12 months in patients with beta-thalassemia major undergoing allogenic BMT randomized to zoledronic acid versus placebo. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To describe the percent change in total hip BMD at 12 months in the two study arms. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To compare the changes in bone turn over markers at 3, 6, and 12 months in the two treatment arms. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To describe the incidence rate of all clinical fractures at 1 year in the two study arms. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To describe the general safety of zoledronic acid. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To describe the percent change in lumbar spine (L1 to L4) BMD and total hip BMD at 6 months when available. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: November 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intervention
Patients in this arm received zoledronic acid.
 Drug: Zoledronic acid
Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
Other Name: Zometa
Placebo Comparator: Control
Patients in this arm received placebo as control group
 Drug: Placebo
Placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent.
  • Patients must be 18 years old and over.
  • Diagnosed with beta-thalassemia major
  • Scheduled for allogenic bone marrow transplantation
  • The date of randomization must be no more than 1 week after BMT.
  • Patients must be accessible for follow-up.
  • Life expectancy of at least 12 months from randomization.

Exclusion Criteria:

  • Patients with any clinical or radiological evidence of existing fracture in the lumbar spine and/or total hip.
  • Patients with a history of fracture with low-density or no associated trauma.
  • Osteoporotic patients with T-score <= -2.5
  • Previous treatment with a bisphosphonate.
  • Patients with abnormal renal function as evidenced by either a serum creatinine determination 1.5 x or greater above the upper limit of normal or by a calculated creatinine clearance of 30 ml/minute or less.
  • Pregnancy and lactation.
  • Women of childbearing potential not on a medically recognized form of contraception.
  • Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study.
  • Subjects participating simultaneously in studies with unapproved drugs, indications or treatment regimens.
  • Known hypersensitivity to zoledronic acid or bisphosphonates.
  • Patients with prior exposure to anabolic steroids, growth hormone, Parathyroid Hormone (PTH) or other drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate).
  • Serious intercurrent illness
  • History of metabolic bone diseases
  • History of corticosteroid treatment for other causes
  • History of antiepileptic drug treatment
  • History or surgery at the lumbosacral spine, with or without implantable devices.
  • Any disease of the spine that would preclude the proper acquisition of a lumbar spine DXA.
  • Mental illness that precludes the patient from giving informed consent.
  • Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
  • Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01016093

Locations
Iran, Islamic Republic of
Hematology-Oncology & SCT Research Center
Tehran, Iran, Islamic Republic of, 14114
Sponsors and Collaborators
Tehran University of Medical Sciences
Novartis
  More Information

Additional Information:
Hematology-Oncology and Stem Cell Transplantation Research Center  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Mahdi Jalili MD / Hematology-Oncology and SCT Research Center, Tehran University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01016093     History of Changes
Other Study ID Numbers: HORCSCT-0601
Study First Received: November 17, 2009
Last Updated: July 25, 2011
Health Authority: Iran: Ministry of Health

Keywords provided by Tehran University of Medical Sciences:
Thalassemia
BMT
HSCT

Additional relevant MeSH terms:
Beta-Thalassemia
Thalassemia
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
 Genetic Diseases, Inborn
Zoledronic acid
Diphosphonates
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013